Cyclo Therapeutics Gestion

Gestion contrôle des critères 4/4

Le PDG Cyclo Therapeutics est N. Fine, nommé en Sep2015, a un mandat de 9.17 ans. La rémunération annuelle totale est $ 672.89K, composée du salaire de 80.4% et des bonus 19.6%, y compris les actions et options de la société. détient directement 2.59% des actions de la société, d'une valeur de $ 521.22K. La durée moyenne de mandat de l'équipe de direction et du conseil d'administration est respectivement 7.3 ans et 10 ans.

Informations clés

N. Fine

Directeur général

US$672.9k

Rémunération totale

Pourcentage du salaire du PDG	80.4%
Durée du mandat du directeur général	9.2yrs
Propriété du PDG	2.6%
Durée moyenne d'occupation des postes de direction	7.3yrs
Durée moyenne du mandat des membres du conseil d'administration	10yrs

Mises à jour récentes de la gestion

Recent updates

Cyclo Therapeutics GAAP EPS of -$0.41 beats by $0.12, revenue of $0.54M misses by $0.08M

Aug 16

Here's Why We're A Bit Worried About Cyclo Therapeutics' (NASDAQ:CYTH) Cash Burn Situation

Jul 12

Cyclo Therapeutics posts design protocol of pivotal late-stage study of Trappsol Cyclo

Apr 27

Analyse de la rémunération des PDG

Comment la rémunération de N. Fine a-t-elle évolué par rapport aux bénéfices de Cyclo Therapeutics?
Date	Rémunération totale	Salaire	Bénéfices de l'entreprise
Sep 30 2024	n/a	n/a	-US$25m
Jun 30 2024	n/a	n/a	-US$21m
Mar 31 2024	n/a	n/a	-US$19m
Dec 31 2023	US$673k	US$541k	-US$20m
Sep 30 2023	n/a	n/a	-US$19m
Jun 30 2023	n/a	n/a	-US$19m
Mar 31 2023	n/a	n/a	-US$18m
Dec 31 2022	US$1m	US$541k	-US$15m
Sep 30 2022	n/a	n/a	-US$13m
Jun 30 2022	n/a	n/a	-US$13m
Mar 31 2022	n/a	n/a	-US$13m
Dec 31 2021	US$1m	US$508k	-US$14m
Sep 30 2021	n/a	n/a	-US$14m
Jun 30 2021	n/a	n/a	-US$12m
Mar 31 2021	n/a	n/a	-US$10m
Dec 31 2020	US$489k	US$400k	-US$9m
Sep 30 2020	n/a	n/a	-US$9m
Jun 30 2020	n/a	n/a	-US$9m
Mar 31 2020	n/a	n/a	-US$8m
Dec 31 2019	US$490k	US$400k	-US$8m
Sep 30 2019	n/a	n/a	-US$6m
Jun 30 2019	n/a	n/a	-US$5m
Mar 31 2019	n/a	n/a	-US$5m
Dec 31 2018	US$467k	US$400k	-US$4m
Sep 30 2018	n/a	n/a	-US$4m
Jun 30 2018	n/a	n/a	-US$4m
Mar 31 2018	n/a	n/a	-US$4m
Dec 31 2017	US$441k	US$400k	-US$4m

Rémunération vs marché: La rémunération totale de N. ($USD 672.89K ) est dans la moyenne des entreprises de taille similaire sur le marché US ($USD 650.80K ).

Rémunération et revenus: La rémunération de N. a été cohérente avec les performances de l'entreprise au cours de l'année écoulée.

PDG

N. Fine (67 yo)

9.2yrs

Titularisation

US$672,888

Compensation

Mr. N. Scott Fine has been Chief Executive Officer of Cyclo Therapeutics, Inc. (formerly known as CTD Holdings, Inc.) since September 14, 2015. Mr. Fine served as the Chairman of Cyclo Therapeutics, Inc. s...

Équipe de direction

Nom	Position	Titularisation	Compensation	Propriété
N. Fine	CEO & Director	9.2yrs	US$672.89k	2.59% $ 521.2k
C. Strattan	Founder & Director	no data	US$33.00k	1.29% $ 258.7k
Joshua Fine	CFO & Secretary	10.8yrs	US$463.98k	0.059% $ 11.8k
Michael Lisjak	Senior VP of Business Development & Chief Regulatory Officer	5.3yrs	US$473.21k	0.043% $ 8.7k
Jeffrey Tate	COO, Chief Quality Officer & Director	9.2yrs	US$255.14k	0.32% $ 64.5k
Lori McKenna	Global Head of Patient Advocacy	3.5yrs	pas de données	pas de données
Karen Mullen	Interim Chief Medical Officer	1.8yrs	pas de données	pas de données

7.3yrs

Durée moyenne de l'emploi

66yo

Âge moyen

Gestion expérimentée: L'équipe dirigeante de CYTH est chevronnée et expérimentée (7.3 années d'ancienneté moyenne).

Membres du conseil d'administration

Nom	Position	Titularisation	Compensation	Propriété
N. Fine	CEO & Director	10.8yrs	US$672.89k	2.59% $ 521.2k
C. Strattan	Founder & Director	34.8yrs	US$33.00k	1.29% $ 258.7k
Jeffrey Tate	COO, Chief Quality Officer & Director	14.3yrs	US$255.14k	0.32% $ 64.5k
William Shanahan	Independent Director	8.4yrs	US$40.13k	0.52% $ 104.3k
Markus Sieger	Independent Chairman	10.8yrs	US$66.38k	1.33% $ 267.8k
Rita Colwell	Co-Chair of Scientific Advisory Board	no data	pas de données	pas de données
Sharon Hrynkow	Co-Chairman of Scientific Advisory Board	10yrs	US$600.09k	pas de données
F. Ostronic	Independent Vice Chairman	10.6yrs	US$41.25k	1.22% $ 244.4k
Caroline Hastings	Member of Scientific Advisory Board	9.7yrs	pas de données	pas de données
Benny Liu	Member of Scientific Advisory Board	9.5yrs	pas de données	pas de données
Gerald F. Cox	Member of Scientific Advisory Board	3.2yrs	pas de données	pas de données
Randall Toig	Independent Director	6.7yrs	US$35.63k	0.51% $ 102.2k

10.0yrs

Durée moyenne de l'emploi

67yo

Âge moyen

Conseil d'administration expérimenté: Le conseil d'administration de la CYTH est chevronné et expérimenté ( 10 années d'ancienneté moyenne).

Cyclo Therapeutics Gestion

Gestion contrôle des critères 4/4

Informations clés

Mises à jour récentes de la gestion

Insufficient new directors

CEO & Director exercised options to buy US$293k worth of stock.

Cyclo Therapeutics, Inc. Appoints Vivien Wong as Member of the Board

Cyclo Therapeutics, Inc., Annual General Meeting, Jul 31, 2023

Cyclo Therapeutics, Inc. Appoints William Conkling to Serve as Director

CEO & Director recently bought US$213k worth of stock

Recent updates

New major risk - Financial position

Third quarter 2024 earnings: EPS and revenues miss analyst expectations

Cyclo Therapeutics Receives Two Letters from Nasdaq Due to Non-Compliance with Multiple Nasdaq Listing Rules

Insufficient new directors

Cyclo Therapeutics, Inc. announced that it has received $3 million in funding from Rafael Holdings, Inc.

Rafael Holdings, Inc. (NYSE:RFL) entered into a definitive agreement to acquire unknown remaining stake of Cyclo Therapeutics, Inc. (NasdaqCM:CYTH).

New minor risk - Share price stability

Second quarter 2024 earnings: EPS and revenues miss analyst expectations

Cyclo Therapeutics, Inc. announced that it has received $2 million in funding from Rafael Holdings, Inc.

Cyclo Therapeutics, Inc. Achieves Landmark Milestone with Completion of Enrollment of Last Patient in Phase 3 Pivotal TransportNPC Trial of Niemann-Pick Type C1

Consensus EPS estimates fall by 12%

First quarter 2024 earnings: EPS exceeds analyst expectations while revenues lag behind

Full year 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

New minor risk - Profitability

Cyclo Therapeutics, Inc. (NasdaqCM:CYTH) completed the acquisition of Applied Molecular Transport Inc. (NasdaqCM:AMTI) from a group of shareholders for $10.2 million.

Cyclo Therapeutics, Inc. (NasdaqCM:CYTH) completed the acquisition of Applied Molecular Transport Inc. (NasdaqCM:AMTI) from a group of shareholders for $10.2 million.

Cyclo Therapeutics, Inc. Announces Positive Outcome from Type C Meeting with U.S. FDA Discussing Trappsol Cyclo Clinical Program for Treatment of Niemann-Pick Disease Type C1

Cyclo Therapeutics Receives Written Notice from Nasdaq Regarding Non-Compliance with the Minimum Stockholders’ Equity Requirement Under Nasdaq Listing Rule 5550(b)

Third quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

New major risk - Share price stability

CEO & Director exercised options to buy US$293k worth of stock.

Consensus revenue estimates decrease by 29%, EPS upgraded

Cyclo Therapeutics, Inc. (NasdaqCM:CYTH) entered into a definitive agreement to acquire Applied Molecular Transport Inc. (NasdaqCM:AMTI) for $11.9 million.

Cyclo Therapeutics, Inc. (NasdaqCM:CYTH) entered into a definitive agreement to acquire Applied Molecular Transport Inc. (NasdaqCM:AMTI) for $11.9 million.

Cyclo Therapeutics, Inc. Appoints Vivien Wong as Member of the Board

New major risk - Revenue size

Second quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Cyclo Therapeutics, Inc. announced that it has received $5 million in funding from Rafael Holdings, Inc.

Cyclo Therapeutics, Inc., Annual General Meeting, Jul 31, 2023

First quarter 2023 earnings: EPS and revenues miss analyst expectations

Cyclo Therapeutics, Inc. Appoints William Conkling to Serve as Director

CEO & Director recently bought US$213k worth of stock

Full year 2022 earnings: EPS and revenues miss analyst expectations

Cyclo Therapeutics, Inc. Provides Clinical Program Update

Cyclo Therapeutics Announces First Patient Dosed in Phase 2b Study of Trappsol® Cyclo™ for the Treatment of Early Alzheimer’s Disease

Consensus forecasts updated

Third quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Third quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Cyclo Therapeutics, Inc. Announces Publication of Phase 1 Data for Trappsol® Cyclo™ for the Treatment of Niemann-Pick Disease Type C1 (NPC1)

Cyclo Therapeutics Commences Phase 2B Study of Trappsol Cyclo for the Treatment of Early Alzheimer’S Disease

Second quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Cyclo Therapeutics GAAP EPS of -$0.41 beats by $0.12, revenue of $0.54M misses by $0.08M

Here's Why We're A Bit Worried About Cyclo Therapeutics' (NASDAQ:CYTH) Cash Burn Situation

First quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Cyclo Therapeutics, Inc., Annual General Meeting, Jun 24, 2022

Price target decreased to US$10.00

Consensus revenue estimates increase by 16%

Full year 2021 earnings: Revenues exceed analysts expectations while EPS lags behind

Cyclo Therapeutics to Present Overview of Pivotal Phase 3 Study for Lead Candidate, Trappsol® Cyclo™, at WORLDSymposium 2022

We're A Little Worried About Cyclo Therapeutics' (NASDAQ:CYTH) Cash Burn Rate

Cyclo Therapeutics, Inc. Receives IND Clearance from the U.S. FDA to Advance its Phase 2 Study of Trappsol® Cyclo™ for the Treatment of Alzheimer’s Disease

Independent Vice Chairman recently bought US$53k worth of stock

Third quarter 2021 earnings released: US$0.60 loss per share (vs US$0.94 loss in 3Q 2020)

Cyclo Therapeutics: Addressing The Fundamentals Of Alzheimer's Disease

Will Cyclo Therapeutics (NASDAQ:CYTH) Spend Its Cash Wisely?

Second quarter 2021 earnings released: US$0.56 loss per share (vs US$1.60 loss in 2Q 2020)

Consensus forecasts updated

Cyclo Therapeutics, Inc. Commences Patient Enrollment in TransportNPC, a Pivotal Phase 3 Study Evaluating Trappsol® Cyclo™ in Niemann-Pick Type C1

Cyclo Therapeutics Provides Update on Trappsol® Cyclo

Cyclo therapeutics to join Russell 2000 Index

We're Keeping An Eye On Cyclo Therapeutics' (NASDAQ:CYTH) Cash Burn Rate

Cyclo Therapeutics Provides Business Update

First quarter 2021 earnings released: US$0.76 loss per share (vs US$2.18 loss in 1Q 2020)

Cyclo Therapeutics, Inc. Announces Design of Pivotal Phase 3 Study Evaluating Trappsol Cyclo in Niemann-Pick Type C1

Cyclo Therapeutics posts design protocol of pivotal late-stage study of Trappsol Cyclo

Independent Chairman recently bought US$81k worth of stock

Full year 2020 earnings released: US$5.59 loss per share (vs US$6.96 loss in FY 2019)

Earnings beat expectations, revenue disappoints

Analyse de la rémunération des PDG